Safety evaluation of the food enzyme glucose oxidase from *Aspergillus niger* (strain ZGL)

EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (EFSA CEP Panel), Vittorio Silano, José Manuel Barat Baviera, Claudia Bolognesi, Beat Johannes Brüschweiler, Pier Sandro Cocconcelli, Riccardo Crebelli, David Michael Gott, Konrad Grob, Evgenia Lampi, Alicja Mortensen, Gilles Rivière, Inger-Lise Steffensen, Christina Tlustos, Henk Van Loveren, Laurence Vernis, Holger Zorn, Boet Glandorf, Lieve Herman, Klaus-Dieter Jany*, Sirpa Kärenlampi*, André Penninks*, Davor Željezić*, Margarita Aguileria-Gómez, Davide Arcella, Christine Horn, Natália Kovalkovicová, Yi Liu, Joaquim Manuel Maia and Andrew Chesson

Abstract

The food enzyme glucose oxidase (β-D-glucose:oxygen 1-oxidoreductase; EC 1.1.3.4) is produced with a genetically modified *Aspergillus niger* strain ZGL by DSM Food Specialties B.V.. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The glucose oxidase is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the food enzyme-total organic solids (TOS) was estimated to be up to 0.004 mg TOS/kg body weight (bw) per day. The toxicity studies were carried out with an asparaginase from *A. niger* (strain ASP). The Panel considered this enzyme as a suitable substitute to be used in the toxicological studies, because they derive from the same recipient strain, the location of the inserts are comparable, no partial inserts were present and the production methods are essentially the same. Genotoxicity tests did not raise a safety concern. The systemic toxicity was assessed by means of a repeated dose 90-day oral toxicity study in rats. The Panel identified a no observed adverse effect level (NOAEL) at the highest dose of 1,038 and 1,194 mg TOS/kg bw per day (for males and females, respectively) that, compared with the estimated dietary exposure, results in a sufficiently high margin of exposure (MoE) (of at least 260,000). Similarity of the amino acid sequence to those of known allergens was searched and one match was found. The Panel considered that, under the intended conditions of use, the risk of allergic sensitisation and elicitation reactions by dietary exposure cannot be excluded, but the likelihood to occur is considered to be low. Based on the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns under the intended conditions of use.

© 2019 European Food Safety Authority. *EFSA Journal* published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

**Keywords:** food enzyme, glucose oxidase, EC 1.1.3.4, beta-β-glucose:oxygen 1-oxidoreductase, β-glucose oxidase, *Aspergillus niger*, genetically modified microorganism

**Requestor:** European Commission

**Question number:** EFSA-Q-2013-01005

**Correspondence:** fip@efsaeuropa.eu

* Member of the former Working Group on ‘Enzymes’ of the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF).
Panel members: José Manuel Barat Baviera, Claudia Bolognesi, Beat Johannes Brüschweiler, Andrew Chesson, Pier Sandro Cocconcelli, Riccardo Crebelli, David Michael Gott, Konrad Grob, Evgenia Lampi, Alicja Mortensen, Gilles Riviere, Vittorio Silano, Inger-Lise Steffensen, Christina Tlustos, Henk Van Loveren, Laurence Vernis, Holger Zorn.

Note: The full opinion will be published in accordance with Article 12 of Regulation (EC) No 1331/2008 once the decision on confidentiality will be received from the European Commission.

Acknowledgements: The CEP Panel wishes to thank all members of the Working Group on Food Enzymes of the former EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) and former EFSA staff Zoltan Divéki for the preparatory work on this scientific output. The CEP Panel wishes to acknowledge all European competent institutions, Member State bodies and other organisations that provided data for this scientific output.

Suggested citation: EFSA CEP Panel (EFSA Panel on Food Contact Materials, Enzymes and Processing Aids), Silano V, Barat Baviera JM, Bolognesi C, Brüschweiler BJ, Cocconcelli PS, Crebelli R, Gott DM, Grob K, Lampi E, Mortensen A, Riviere G, Steffensen I-L, Tlustos C, Van Loveren H, Vernis L, Zorn H, Glandorf B, Herman L, Jany K-D, Kärenlampi S, Penninks A, Zelježić D, Aguilera-Gómez M, Arcella D, Horn C, Kovalkovícová N, Liu Y, Maia JM and Chesson A, 2019. Scientific Opinion on the safety evaluation of the food enzyme glucose oxidase from Aspergillus niger (strain ZGL). EFSA Journal 2019;17(3):5629, 17 pp. https://doi.org/10.2903/j.efsa.2019.5629

ISSN: 1831-4732

© 2019 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.
Table of contents

Abstract ................................................................................................................................................... 1
1. Introduction ................................................................................................................................ 4
   1.1. Background and Terms of Reference as provided by the requestor ............................................ 4
   1.1.1. Background as provided by the European Commission .............................................................. 4
   1.1.2. Terms of Reference ..................................................................................................................... 4
   1.2. Interpretation of the Terms of Reference ....................................................................................... 5
2. Data and Methodologies .................................................................................................................... 5
   2.1. Data ........................................................................................................................................... 5
   2.2. Methodologies ............................................................................................................................. 5
3. Assessment ........................................................................................................................................ 5
   3.1. Source of the food enzyme ........................................................................................................... 5
   3.1.1. Characteristics of the parental and recipient microorganisms .................................................... 5
   3.1.2. Characteristics of introduced sequences ..................................................................................... 6
   3.1.3. Description of the genetic modification process ......................................................................... 6
   3.1.4. Safety aspects of the genetic modification .................................................................................. 6
   3.2. Production of the food enzyme ..................................................................................................... 7
   3.3. Characteristics of the food enzyme ............................................................................................... 7
   3.3.1. Properties of the food enzyme .................................................................................................... 7
   3.3.2. Chemical parameters ................................................................................................................ 8
   3.3.3. Purity .......................................................................................................................................... 8
   3.3.4. Viable cells and DNA of the production strain ........................................................................... 8
   3.4. Toxicological data ........................................................................................................................ 9
   3.4.1. Choice of test item ...................................................................................................................... 9
   3.4.2. Genotoxicity ............................................................................................................................... 9
   3.4.2.1. Bacterial reverse mutation test ................................................................................................ 9
   3.4.2.2. In vitro mammalian chromosomal aberration test ................................................................. 10
   3.4.3. Repeated dose 90-day oral toxicity study in rodents ................................................................. 10
   3.4.4. Allergenicity ............................................................................................................................... 10
   3.5. Dietary exposure .......................................................................................................................... 11
   3.5.1. Intended use of the food enzyme ............................................................................................... 11
   3.5.2. Dietary exposure estimation ....................................................................................................... 11
   3.5.3. Uncertainty analysis ................................................................................................................... 12
   3.6. Margin of exposure ....................................................................................................................... 13
4. Conclusions ....................................................................................................................................... 13
Documentation provided to EFSA .......................................................................................................... 13
References ........................................................................................................................................... 13
Abbreviations ...................................................................................................................................... 15
Appendix A – Dietary exposure estimates to the food enzyme-TOS in details ......................................... 16
Appendix B – Population groups considered for the exposure assessment ............................................ 17
1. Introduction

Article 3 of the Regulation (EC) No. 1332/2008\(^1\) provides definition for ‘food enzyme’ and ‘food enzyme preparation’.

‘Food enzyme’ means a product obtained from plants, animals or micro-organisms or products thereof including a product obtained by a fermentation process using micro-organisms: (i) containing one or more enzymes capable of catalysing a specific biochemical reaction; and (ii) added to food for a technological purpose at any stage of the manufacturing, processing, preparation, treatment, packaging, transport or storage of foods.

‘Food enzyme preparation’ means a formulation consisting of one or more food enzymes in which substances such as food additives and/or other food ingredients are incorporated to facilitate their storage, sale, standardisation, dilution or dissolution.

Before January 2009, food enzymes other than those used as food additives were not regulated or were regulated as processing aids under the legislation of the Member States. On 20 January 2009, Regulation (EC) No. 1332/2008 on food enzymes came into force. This Regulation applies to enzymes that are added to food to perform a technological function in the manufacture, processing, preparation, treatment, packaging, transport or storage of such food, including enzymes used as processing aids. Regulation (EC) No. 1331/2008\(^2\) established the European Union (EU) procedures for the safety assessment and the authorisation procedure of food additives, food enzymes and food flavourings. The use of a food enzyme shall be authorised only if it is demonstrated that:

i) it does not pose a safety concern to the health of the consumer at the level of use proposed;
ii) there is a reasonable technological need;
iii) its use does not mislead the consumer.

All food enzymes currently on the European Union market and intended to remain on that market, as well as all new food enzymes, shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) and approval via an EU Community list.

The ‘Guidance on submission of a dossier on food enzymes for safety evaluation’ (EFSA CEF Panel, 2009) lays down the administrative, technical and toxicological data required.

1.1. Background and Terms of Reference as provided by the requestor

1.1.1. Background as provided by the European Commission

Only food enzymes included in the European Union (EU) Community list may be placed on the market as such and used in foods, in accordance with the specifications and conditions of use provided for in Article 7 (2) of Regulation (EC) No 1332/2008 on food enzymes.

Two applications have been introduced by the companies “DSM Food Specialties B.V” for the authorisation of the food enzymes Glucose oxidase from a genetically modified strain of *Aspergillus niger* (strain ZGL) and Phosphodiesterase I from *Leptographium procerum* (strain FDA).

Following the requirements of Article 12.1 of Regulation (EC) No 234/2011\(^3\) implementing Regulation (EC) No 1331/2008, the Commission has verified that the two application fall within the scope of the food enzyme Regulation and contain all the elements required under Chapter II of that Regulation.

1.1.2. Terms of Reference

The European Commission requests the European Food Safety Authority to carry out the safety assessments on the food enzymes glucose oxidase from a genetically modified strain of *Aspergillus niger* (strain ZGL) and phosphodiesterase I from *Leptographium procerum* (strain FDA) in accordance with Article 17.3 of Regulation (EC) No 1332/2008 on food enzymes.

---

\(^1\) Regulation (EC) No. 1332/2008 of the European Parliament and of the Council of 16 December 2008 on Food Enzymes and Amending Council Directive 83/417/EEC, Council Regulation (EC) No. 1493/1999, Directive 2000/13/EC, Council Directive 2001/112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, pp. 7–15.

\(^2\) Regulation (EC) No. 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, pp. 1–6.

\(^3\) Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the European Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 64, 11.3.2011, p. 15-24.
1.2. Interpretation of the Terms of Reference

The present scientific opinion addresses the European Commission’s request to carry out the safety assessment of food enzyme glucose oxidase from a genetically modified *Aspergillus niger* (strain ZGL).

2. Data and Methodologies

2.1. Data

The applicant has submitted a dossier in support of the application for authorisation of the food enzyme glucose oxidase from a genetically modified *A. niger* (strain ZGL).

Additional information was requested from the applicant during the assessment process on 31 October 2014, 7 November 2014, 24 March 2015, 17 June 2015, 11 April 2017, 12 July 2017, 23 February 2018 and 25 June 2018, and was consequently provided (see ‘Documentation provided to EFSA’).

2.2. Methodologies

The assessment was conducted in line with the principles described in the EFSA ‘Guidance on transparency in the scientific aspects of risk assessment’ (EFSA, 2009) as well as in the EFSA ‘Scientific Opinion on Guidance on the risk assessment of genetically modified microorganisms and their products intended for food and feed use’ (EFSA GMO Panel, 2011) and following relevant guidelines of the EFSA Scientific Committees.

The current ‘Guidance on the submission of a dossier on food enzymes for safety evaluation’ (EFSA CEF Panel, 2009) has been followed for the evaluation of the application with the exception of the exposure assessment, which was carried out in accordance to the methodology described in the CEF Panel statement on the exposure assessment of food enzymes (EFSA CEF Panel, 2016).

3. Assessment

IUBMB nomenclature: Glucose oxidase

Systematic name: Beta-β-glucose:oxygen 1-oxidoreductase

Synonyms: Glucose oxyhydrase, β-β-glucose oxidase, β-glucose oxidase

IUBMB No.: EC 1.1.3.4

CAS No.: 9001-37-0

EINECS No.: 232-601-0

The glucose oxidase catalyses the oxidation of glucose to d-glucono-1,5-lactone (glucono-δ-lactone), thereby reducing molecular oxygen to hydrogen peroxide. It is intended to be used in baking processes.

3.1. Source of the food enzyme

The glucose oxidase is produced with a genetically modified filamentous fungus *A. niger* strain ZGL. According to the CEF Guidance, the certificate of deposit of the strain in a public validated culture collection should be provided. The Panel noted that this would not allow a verification of the strain independently of the company.

3.1.1. Characteristics of the parental and recipient microorganisms

---

4 Technical dossier/Additional information January 2015 (22).

5 Technical dossier/Annex II-2.
3.1.2. Characteristics of introduced sequences

3.1.3. Description of the genetic modification process
3.1.4. Safety aspects of the genetic modification

The technical dossier contains all necessary information on the recipient microorganism, the donor organism and the genetic modification process.

The production strain *A. niger* ZGL differs from the parental strain

The consistency of enzyme activity observed in three batches intended for commercialisation (Table 1) indicates that the production strain is phenotypically stable. Genotypic stability was confirmed

No issues of concern arising from the genetic modifications were identified by the Panel.

3.2. Production of the food enzyme

The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No. 852/2004\(^8\), with food safety procedures based on Hazard Analysis and Critical Control Points (HACCP), and in accordance with current Good Manufacturing Practice (GMP).

The production strain is grown as a pure culture using a typical industrial medium in a submerged, fed-batch fermentation system with conventional process controls in place. After completion of the fermentation, cells are killed and the solid biomass is removed from the fermentation broth by filtration leaving a supernatant containing the food enzyme. The filtrate containing the enzyme is then further purified and concentrated, including an ultrafiltration step in which enzyme protein is retained while most of the low molecular weight material passes the filtration membrane and is discarded. The applicant provided information on the identity of the substances used to control the fermentation and in the subsequent downstream processing of the food enzyme.

The applicant mentions that the use of microfiltration is an option for further production. However, only the filter press procedure is currently applied in regular production and no experimental data was provided on the recovery route using microfiltration.\(^9\) Thus, only the filter press procedure was assessed by the Panel.

The Panel considered that sufficient information has been provided on the manufacturing process and the quality assurance system implemented by the applicant to exclude issues of concern.

3.3. Characteristics of the food enzyme

3.3.1. Properties of the food enzyme

The glucose oxidase is a single polypeptide chain of 604 amino acids, including a signal peptide of 18 amino acids. The molecular mass of the mature protein, derived from the amino acid sequence, was calculated to be 66.3 kDa. The homogeneity was investigated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) analysis. Gels presented for three independent enzyme batches were comparable, showing the target protein migrating at about 66 kDa. No enzymatic side activities were reported.

The in-house determination of glucose oxidase activity is based on the oxidation of glucose into \(\delta\)-gluco-1,5-lactone (gluco \(\delta\)-lactone) (reaction condition: 37°C, pH 5.4), resulting in the formation of hydrogen peroxide, followed by the oxidation of 2,2’-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid (ABTS) in the presence of peroxidase. ABTS is measured spectrophotometrically at 405 nm. The enzyme activity is expressed in Glucose Oxidase from *Penicillium* Units (GOPU)/g. One GOPU is defined as the amount of enzyme that oxidises 3 mg glucose to glucono \(\delta\)-lactone under the given standard conditions (reaction condition: 35°C, pH 5.1, incubation time: 15 min).\(^10\)

---

8 Regulation (EC) No. 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of food additives. OJ L 226, 25.6.2004, pp. 3–21.

9 Technical dossier/Additional information June 2017.

10 Technical dossier/Annex I-2.
The food enzyme has been characterised with regard to its temperature and pH profiles. It has a temperature maximum around 35°C (pH 5.4) and a pH maximum around pH 5-5.5 (37°C). Thermostability was tested after a pre-incubation of the food enzyme for 2-60 min at different temperatures. Under the conditions (pH 5.4) of the applied temperature stability assay, glucose oxidase activity decreased above 55°C showing no residual activity above 70°C after 2 min.4

3.3.2. Chemical parameters

Data on the chemical parameters of the food enzyme were provided for three batches used for commercialisation (Table 1).11 The average total organic solids (TOS) of the three food enzyme batches for commercialisation was 9.3% (range 8.7-9.7%). The average enzyme activity/TOS ratio of the three food enzyme batches for commercialisation is 134 GOPU/mg TOS.

### Table 1: Compositional data of the food enzyme

| Parameter                              | Unit                     | Batches          |
|----------------------------------------|--------------------------|------------------|
| Glucose oxidase activity               | GOPU/g batch(a)          | 10,900           |
| Protein                                | %                        | 5.8              |
| Ash                                    | %                        | 0.2              |
| Water                                  | %                        | 90.1             |
| Total organic solids (TOS)(b)          | %                        | 9.7              |
| Glucose oxidase activity/mg TOS        | GOPU/mg TOS              | 112              |

(a): GOPU: Glucose Oxidase from *Penicillium* Units (see Section 3.3.1).
(b): TOS calculated as 100% – % water – % ash.

3.3.3. Purity

The food enzyme complies with the specification for lead (≤ 5 mg/kg) as laid down in the general specifications and considerations for enzymes used in food processing (FAO/WHO, 2006).12,13

The food enzyme complies with the microbiological criteria as laid down in the general specifications and considerations for enzymes used in food processing (FAO/WHO, 2006), which stipulate that *E. coli* and *Salmonella* species are absent in 25 g of sample and total coliforms should not exceed 30 colony forming unit (CFU) per gram.14 No antimicrobial activity was detected in any of these batches (FAO/WHO, 2006).14

Strains of *Aspergillus* in common with most filamentous fungi have the capacity to produce a range of secondary metabolites (Frisvad et al., 2018). The applicant did not provide information on the secondary metabolites produced under the conditions of fermentation which might contribute to the food enzyme–TOS. The absence of ochratoxin A and fumonisins was demonstrated. The possible presence of other secondary metabolites is addressed by the toxicological examination of the food enzyme–TOS.15,16

The Panel considered that the information provided on the purity of the food enzyme is sufficient.

3.3.4. Viable cells and DNA of the production strain

The absence of the production strain in the food enzyme at the end of the killing was demonstrated.

The absence of recombinant DNA in the food enzyme was demonstrated.

---

11 Technical dossier/Additional information April 2018.
12 Limit of detection (LOD): Pb = 0.006 mg/L.
13 Technical dossier/Annex I-3, Annex I-4 and Additional information January 2015 (22).
14 Technical dossier/Annex I-3.
15 Limit of quantification (LOQ): Ochratoxin A = 0.1 µg/kg; Fumonisins (B₁, B₂ and B₃) = 10 µg/kg each toxin.
16 Technical dossier/Annex I-3 and Additional information January 2015.
17 Technical dossier/Annex II-19 Additional information January 2015 and Additional information June 2017.
The Panel also considered the information on the absence of viable cells and recombinant DNA of the production strain as sufficient as long as the filter press is used during the manufacturing process. The Panel noted that for the manufacturing processes involving microfiltration, the absence of the recombinant DNA in the food enzyme cannot be assessed due to absence of data.

3.4. Toxicological data

3.4.1. Choice of test item

No toxicological studies were provided for the glucose oxidase food enzyme produced with the \textit{A. niger} strain ZGL. Instead, the applicant argued that the assessment of this glucose oxidase produced by \textit{A. niger} strain ZGL could be based on toxicological data from another food enzyme - an asparaginase produced with the \textit{A. niger} strain ASP, previously submitted to EFSA (Question No EFSA-Q-2013-00895) following the EFSA guidance (EFSA CEF Panel, 2009).

The focus of the toxicological studies of food enzymes is the assessment of non-protein components of TOS. Only rarely is the enzyme protein itself considered a potential hazard.

The production strain of the asparaginase was developed from the same recipient strain (\textit{A. niger} ZGL) as that for the glucose oxidase under assessment (\textit{A. niger} ASP). Therefore, the genetic differences between \textit{A. niger} ZGL and \textit{A. niger} ASP are not expected to result in a different toxigenic potential.

The batch of asparaginase food enzyme from the \textit{A. niger} strain ASP, used for toxicological studies, was produced according to a standard procedure similar to the one described in section 3.2 of this opinion.\footnote{Technical dossier/Additional information September 2017.} According to the data provided by the applicant, the raw materials used and the steps involved in the manufacturing of the asparaginase and glucose oxidase food enzymes from \textit{A. niger} strains (ASP and ZGL, respectively) are essentially the same in both processes, and the temperature and pH conditions used during fermentation are similar. To produce the final non-formulated ASP batch used for toxicological testing, an additional spray-drying step was performed. The spray-dried batch compared to the mean of ASP commercial batches resulted in a similar specific activity of 38.5 vs. 38.1 Asparaginase Units (ASPU)/mg TOS and a higher level of inorganic constituents.

Taking the microbiological and technical data into account, the Panel considered the asparaginase as a suitable substitute for the glucose oxidase in the toxicological studies.

3.4.2. Genotoxicity

3.4.2.1. Bacterial reverse mutation test

A bacterial reverse mutation assay (Ames test) was made according to Organisation for Economic Co-operation and Development (OECD) Test Guideline 471 (OECD, 1997a) and following Good Laboratory Practice (GLP).\footnote{Technical dossier/Annex I-8.} Four strains of \textit{Salmonella} Typhimurium (TA1535, TA100, TA1537 and TA98) and \textit{E. coli} WP2uvrA were used in the presence or absence of metabolic activation (S9-mix), applying the ‘plate incorporation assay’. One experiment in triplicate was performed using five different concentrations of the food enzyme (62, 185, 556, 1,667 and 5,000 \(\mu\)g/plate, corresponding to ca. 56, 166, 499, 1,495 and 4,484 \(\mu\)g TOS/plate). No cytotoxicity was observed at any concentration level of the test substance. Upon treatment with the food enzyme there was no significant increase in revertant colony numbers above the control values in any strain with or without S9-mix.
The Panel concluded that the food enzyme asparaginase did not induce gene mutations under the test conditions employed in this study.

**3.4.2.2. In vitro mammalian chromosomal aberration test**

An *in vitro* mammalian chromosomal aberration test was carried out according to the OECD Test Guideline 473 (OECD, 1997b) and following GLP in human peripheral blood lymphocytes with and without metabolic activation (S9-mix).²¹

In a first experiment the cultures were exposed at concentrations of 2,000, 3,000 and 5,000 μg of food enzyme/mL (corresponding to ca. 1,794, 2,690 and 4,484 μg TOS/mL) applying a 4 + 24 h treatment in the presence and absence of S9-mix, and a continuous treatment 24 + 24 h treatment without S9-mix. In a second experiment, 3,000, 4,000 and 5,000 μg of food enzyme/ml (corresponding to ca. 2,690, 3,587 and 4,484 μg TOS/mL) were tested in a pulse treatment 4 + 24 h with the S9-mix. A slight cytotoxicity was observed after the pulse treatment with and without metabolic activation. The test substance did not induce a significant increase in structural or numerical chromosome aberrations in cultured human blood lymphocytes, in either of the two independently repeated experiments.

The Panel concluded that the food enzyme did not induce chromosome aberrations in cultured human blood lymphocytes, under the test conditions employed for this study.

**3.4.3. Repeated dose 90-day oral toxicity study in rodents**

The repeated dose 90-day oral toxicity study was performed in accordance with OECD Test Guideline 408 (OECD, 1998) and following GLP.²² Groups of 20 male and 20 female Wistar rats received 0.2%, 0.6% or 1.8% of the food enzyme in the diet in doses corresponding to 117, 351 and 1,038 mg TOS/kg body weight (bw) per day for males, and 135, 405 and 1,194 mg TOS/kg bw per day for females. Controls received the same diet with no enzyme added.

No mortality was observed.

Among haematology parameters the absolute number and the percentage of monocytes were statistically significantly increased in high-dose males on day 8 of the study, but not on day 44 or at termination. Therefore, the Panel considered these findings as incidental. The number (in all male dose groups) and percentage (in low- and high-dose males) of basophiles were statistically significantly decreased at termination. As the differences to controls were minor, the decreases were not dose-related and other related effects were absent, these findings were not considered to be of toxicological significance.

Clinical chemistry examination revealed a statistically significantly increased blood urea concentration in low- and mid-dose females on day 44 (mmol/L: 6.2 ± 0.2 and 7.2 ± 0.7 vs 5.6 ± 0.1 in the control group). As these findings were not observed at termination, the differences to controls were minor and not dose related they were considered as incidental and not of toxicological significance.

In urinalysis, the microscopy of the sediment revealed a slight but statistically significant increase in triple phosphate crystals in high-dose males, which were not considered of toxicological importance.

The relative weights of testes (8.38 g/kg bw) and epididymides (3.49 g/kg bw) in the low-dose group were statistically significantly lower than in controls (9.18 g/kg bw and 3.69 g/kg bw, respectively). As these findings were not present at higher doses and were not associated with any microscopically changes in these organs they were considered as incidental and not of toxicological relevance.

No other significant effects were observed.

The Panel identified a no observed adverse effect level (NOAEL) at the highest dose tested equal to 1,038 and 1,194 mg TOS/kg bw per day for males and females, respectively.

**3.4.4. Allergenicity**

The allergenicity assessment considers only the food enzyme and not any carrier or other excipient, which may be used in the final formulation.

---

²¹ Technical dossier/Annex I-9.
²² Technical dossier/Annex I-10.
The potential allergenicity of glucose oxidase produced with the genetically modified strain of \textit{A. niger} strain ZGL was assessed by comparing its amino acid sequence with those of known allergens according to the scientific opinion on the assessment of allergenicity of genetically modified plants and microorganisms and derived food and feed of the Scientific Panel on Genetically Modified Organisms (EFSA GMO Panel, 2017). Using higher than 35\% identity in a window of 80 amino acids as the criterion, one match was found.

The matching allergen was mala s 12 glucose-methanolcholine (GMC) oxidoreductase, from \textit{Malassezia sympodialis} (formerly known as \textit{Pityrosporum}), which is a ubiquitous component of the human skin microbiome.\textsuperscript{23} Mala s 12 has sequence similarity with the glucose-methanol-choline oxidoreductase enzyme superfamily (Zargari et al., 2007), which also includes glucose oxidase. Mala s 12 is a known contact allergen that can induce immunoglobulin E (IgE)- and T-cell-mediated allergic reaction in atopic eczema patients characterised by an impaired skin barrier. Considering that oral allergic reactions are mediated by IgE, elicitation reactions upon dietary exposure to this food enzyme cannot be excluded but as the yeast that expresses this allergen is an ubiquitous component of the skin microflora, the likelihood of such elicitation reactions to occur after oral exposure through food is considered to be low.

No information was available on oral sensitisation or elicitation reactions of this glucose oxidase. No allergic reactions upon dietary exposure to any glucose oxidase have been reported in the literature. Therefore, it can be concluded that the likelihood of an allergic reaction upon oral ingestion of this glucose oxidase, produced with the genetically modified \textit{A. niger} strain ZGL, in individuals respiratory sensitised to glucose oxidase, cannot be excluded, but the likelihood of such a reaction to occur is considered to be low.

The Panel considered that, under the intended conditions of use, the risk of allergic sensitisation and elicitation reactions upon dietary exposure to this food enzyme cannot be excluded, but the likelihood of such reactions occurring is considered to be low.

3.5. Dietary exposure

3.5.1. Intended use of the food enzyme

The food enzyme is intended to be used in baking processes at a recommended use level of up to 0.3 mg TOS/kg flour. The glucose oxidase catalyses the oxidation of glucose to d-glucono-1,5-lactone (gluconolactone), thereby reducing molecular oxygen to hydrogen peroxide. The latter is considered to be the active agent responsible for the intended function of glucose oxidase in dough preparation. Hydrogen peroxide reinforces the gluten network via oxidation of cysteine residues and the resulting formation of disulfide bonds (Bonet et al., 2006). In addition, hydrogen peroxide has been shown to induce the formation of dityrosine cross links through oxidative coupling of tyrosine residues in gluten proteins (Tilley et al., 2001; Takasaki et al., 2005). These reactions naturally occur during the preparation of dough; the use of the glucose oxidase is intended to promote these reactions, and thereby improve and/or standardise the rheological properties of the dough. Concerning the reactions of hydrogen peroxide in the dough, there is no expectation of oxidation products other than those normally formed during the dough making and baking processes.

The food enzyme remains in the dough. Based on data provided on thermostability (see Section 3.3.1), it is expected that the glucose oxidase is inactivated during baking processes.

3.5.2. Dietary exposure estimation

Chronic exposure was calculated using the methodology described in the CEF Panel statement on the exposure assessment of food enzymes (EFSA CEF Panel, 2016). The assessment involved selection of relevant food categories from the EFSA Comprehensive European Food Consumption Database and application of process and technical conversion factors (Annex B in EFSA CEF Panel, 2016).

Chronic exposure was calculated by combining the maximum recommended use level provided by the applicant (see Section 3.5.1) with the relevant FoodEx categories (Annex B in EFSA CEF Panel, 2016), based on individual consumption data. Exposure from all FoodEx categories was subsequently summed up, averaged over the total survey period and normalised for bodyweight. This was done for all individuals across all surveys, resulting in distributions of individual average exposure. Based on

\textsuperscript{23} Technical dossier/Annex I-11.
these distributions, the mean and 95th percentile exposures were calculated per survey for the total population and per age class. Surveys with only one day per subject were excluded and high-level exposure/intake was calculated for only those population groups in which the sample size was sufficiently large to allow calculation of the 95th percentile (EFSA, 2011).

Table 2 provides an overview of the derived exposure estimates across all surveys. Detailed average and 95th percentile exposure to the food enzyme–TOS per age class, country and survey, as well as contribution from each FoodEx category to the total dietary exposure are reported in Appendix A – Tables 1 and 2. For the present assessment, food consumption data were available from 35 different dietary surveys (covering infants, toddlers, children, adolescents, adults and the elderly), carried out in 22 European countries (Appendix B).

### Table 2: Summary of estimated dietary exposure to food enzyme–TOS in six population groups

| Population group | Estimated exposure (mg TOS/kg body weight per day) |
|------------------|-----------------------------------------------------|
|                  | Infants     | Toddlers   | Children   | Adolescents | Adults     | The elderly |
| Age range (months) | 3–11     | 12–35 months | 3–9 years | 10–17 years | 18–64 years | ≥ 65 years |
| Min–max (number of surveys) | 0.000–0.001 (10) | 0.001–0.002 (14) | 0.001–0.002 (19) | 0.000–0.001 (18) | 0.000–0.001 (19) | 0.000–0.001 (18) |
| 95th percentile (number of surveys) | 0.000–0.004 (8) | 0.002–0.003 (12) | 0.001–0.003 (19) | 0.001–0.002 (17) | 0.001–0.001 (19) | 0.001–0.001 (18) |

TOS: total organic solids.

### 3.5.3. Uncertainty analysis

In accordance with the guidance provided in the EFSA opinion related to uncertainties in dietary exposure assessment (EFSA, 2006), the following sources of uncertainties have been considered and are summarised in Table 3.

### Table 3: Qualitative evaluation of the influence of uncertainties on the dietary exposure estimate

| Sources of uncertainties | Direction of impact |
|--------------------------|---------------------|
| **Model input data**     |                     |
| Consumption data: different methodologies/representativeness/underreporting/misreporting/no portion size standard | +/-    |
| Use of data from food consumption surveys of a few days to estimate long-term (chronic) exposure for high percentiles (95th percentile) | +       |
| Possible national differences in categorisation and classification of food | +/-    |
| **Model assumptions and factors** |                     |
| FoodEx categories included in the exposure assessment were assumed to always contain the food enzyme–TOS | +       |
| Exposure to food enzyme–TOS was always calculated based on the recommended maximum use level | +       |
| Selection of broad FoodEx categories for the exposure assessment | +       |
| Use of recipe fractions in disaggregation FoodEx categories | +/-    |
| Use of technical factors in the exposure model | +/-    |

TOS: total organic solids.

+ : uncertainty with potential to cause overestimation of exposure; – : uncertainty with potential to cause underestimation of exposure.

The conservative approach applied to the exposure estimate to food enzyme–TOS, in particular assumptions made on the occurrence and use levels of this specific food enzyme, is likely to have led to a considerable overestimation of the exposure to this specific enzyme under the intended condition of use.
3.6. Margin of exposure

A comparison of the NOAEL (1,038 mg TOS/kg bw per day for males and 1,194 mg TOS/kg bw per day for females) from the 90-day study with the derived exposure estimates of 0.000–0.002 mg TOS/kg bw per day at the mean and from 0.000–0.004 mg TOS/kg bw per day at the 95th percentile, resulted in margin of exposure (MoE) of at least 260,000.

The Panel considered the MoE sufficient to accommodate any potential additional uncertainties resulting from read-across from toxicological studies performed on asparaginase, produced using the same recipient strain, as a substitute.

4. Conclusions

Based on the data provided and the derived margin of exposure, the Panel concluded that the food enzyme glucose oxidase produced with the genetically modified A. niger strain ZGL does not give rise to safety concerns under the intended conditions of use.

The CEP Panel considers the food enzyme free from viable cells of the production organism and recombinant DNA.

Documentation provided to EFSA

1) Technical dossier "Glucose oxidase from Aspergillus niger (strain ZGL)". January 2014. Submitted by DSM Food Specialities B.V.
2) Additional information received, in January 2015 (15th). DSM Food Specialities B.V.
3) Additional information received, in January 2015 (22nd). DSM Food Specialities B.V.
4) Additional information received, in September 2015. DSM Food Specialities B.V.
5) Additional information received, in June 2017. DSM Food Specialities B.V.
6) Additional information received, in September 2017. DSM Food Specialities B.V.
7) Additional information received, in April 2018. DSM Food Specialities B.V.
8) Additional information received, in October 2018. DSM Food Specialities B.V.
9) Summary report on toxicological studies and allergenicity related to glucose oxidase from a genetically modified strain of Aspergillus niger (strain ZGL). April 2014. Delivered by FoBiG GmbH (Freiburg, Germany).

References

Andersen MR, Salazar MP, Schaap PJ, van de Vondervoort PJJ, Culley D, Thykaer J, Frisvad JC, Nielsen KF, Albang R, Albermann K, Berka RM, Braus GH, Braus-Stromeyer SA, Corrochano LM, Dai Z, van Dijck PWM, Hofmann G, Lasure LL, Magnuson JK, Menke H, Meijer M, Meijer SL, Nielsen JB, Nielsen ML, van Ooyen AJJ, Pel HJ, Poulsen L, Samson RA, Stani H, Tsang A, van den Brink JM, Atkins A, Aerts A, Shapiro H, Pangilinan J, Salamov A, Lou Y, Lindquist E, Lucas S, Grimwood J, Grigoriev IV, Kubicek CP, Martinez D, van Peij NNME, Roubos JA, Nielsen J and Baker SE, 2011. Comparative genomics of citric-acid-producing Aspergillus niger ATCC 1015 versus enzyme-producing CBS 513.88. Genome Research, 21, 885–897. http://www.genome.org/cgi/doi/10.1101/gr.112169.110

Berka RM, Ward M, Wilson LJ, Hayenga KJ, Kodama KH, Carломagno LP and Thompson SA, 1990. Molecular cloning and deletion of the gene encoding aspergillopepsin A from Aspergillus awamori. Gene, 86, 153–162. https://doi.org/10.1016/0378-1119(90)90274-U

Bonet A, Rosell CM, Caballero PA, Gomez M, Perez-Munuera I and Lluch MA, 2006. Glucose oxidase effect on dough rheology and bread quality: a study from macroscopic to molecular level. Food Chemistry, 99, 408–415. https://doi.org/10.1016/j.foodchem.2005.07.043

van Dijck PW, Selten GC and Hempenius RA, 2003. On the safety of a new generation of DSM Aspergillus niger enzyme production strains. Regulatory Toxicology and Pharmacology, 38, 27–35. https://doi.org/10.1016/S0273-2300(03)00049-7

EFSA (European Food Safety Authority), 2006. Opinion of the Scientific Committee related to uncertainties in dietary exposure assessment. EFSA Journal 2006;5(1):438, 54 pp. https://doi.org/10.2903/j.efsa.2007.438

EFSA (European Food Safety Authority), 2009. Guidance of the Scientific Committee on transparency in the scientific aspects of risk assessments carried out by EFSA. Part 2: general principles. EFSA Journal 2009;7(5):1051, 22 pp. https://doi.org/10.2903/j.efsa.2009.1051

EFSA (European Food Safety Authority), 2011. Use of the EFSA Comprehensive European Food Consumption Database in exposure assessment. EFSA Journal 2011;9(3):2097, 34 pp. https://doi.org/10.2903/j.efsa.2011.2097
EFSA CEF Panel (EFSA Panel on Genetically Modified Organisms), 2011. Scientific Opinion on Guidance on the risk assessment of genetically modified microorganisms and their products intended for food and feed use. EFSA Journal 2011;9(6):2193, 54 pp. https://doi.org/10.2903/j.efsa.2011.2193

EFSA CEF Panel (EFSA Panel on Genetically Modified Organisms), Naegeli H, Birch AN, Casacuberta J, De Schrijver A, Gralak MA, Guerche P, Jones H, Manachini B, Messean A, Nielsen EE, Nogue F, Robaglia C, Rostoks N, Sweet J, Tebbe C, Visioli F, Wal J-M, Eigenmann P, Epstein M, Hoffmann-Sommergruber K, Koning F, Lovik M, Mills C, Moreno FJ, van Loveren H, Selb R and Fernandez Dumont A, 2017. Guidance on allergenicity assessment of genetically modified plants. EFSA Journal 2017;15(5):4862, 49 pp. https://doi.org/10.2903/j.efsa.2017.4862

FAO/WHO (Food and Agriculture Organization of the United Nations/World Health Organization), 2006. General specifications and considerations for enzyme preparations used in food processing in Compendium of food additive specifications. 67th meeting. FAO JECEA Monographs, 3, 63–67. Available online: http://www.fao.org/3/a-a0675e.pdf

Frisvad JC, Møller LLH, Larsen TO, Kumar R and Arnau J, 2018. Safety of the fungal workhorses of industrial biotechnology: update on the mycotoxin and secondary metabolite potential of Aspergillus niger, Aspergillus oryzae, and Trichoderma reesei. Applied Microbiology and Biotechnology, 102, 9481-9515. https://doi.org/10.1007/s00253-018-9354-1

Gines MJ, Dove MJ and Seligy VL, 1989. Aspergillus oryzae has two nearly identical Taka-amylase genes, each containing eight introns. Gene, 79, 107–117. https://doi.org/10.1016/0378-1119(89)90096-6

OECD (Organisation for Economic Co-Operation and Development), 1997a. OECD Guideline for the testing of chemicals, Section 4 Health effects, Test No. 471: Bacterial reverse mutation test. 21 July 1997. 11 pp. Available online: http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en.jsessionid=92f9235aapq-x-oecd-live-01

OECD (Organisation for Economic Co-Operation and Development), 1997b. OECD Guideline for the testing of chemicals, Section 4 Health effects, Test No. 473: In vitro mammalian chromosomal aberration test. 21 July 1997. 10 pp. Available online: https://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test_9789264071261-en

OECD (Organisation for Economic Co-Operation and Development), 1998. OECD Guideline for the testing of chemicals, Section 4 Health effects, Test No. 408: Repeated dose 90-day oral toxicity study in rodents. 21 September 1998. 10pp. Available online: http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en

Pel HJ, de Winde JH, Archer DB, Dyer PS, Hofmann G, Schaap MA, Turner G, de Vries RP, Albang R, Albermann K, Andersen MR, Bendtsen JD, Benen JAE, van den Berg M, Breestraat S, Caddick MX, Contreras R, Cornell M, Coutinho PM, Danchin EGJ, Debets EGM, Dekker P, van Dijk PWM, van Dijk A, Dijkhuizen L, Driessen AJM, d’Enfert C, Geyssens S, Goosen C, Groot GSP, de Groot PWJ, Guillemette T, Henriass B, Herweijer M, van den Hombergh JPTW, van den Hondel CAMJJ, van der Heijden RTJM, van der Kaaij RM, Klis FM, Kubicek CP, van Kuyk PA, Lauber J, Lu X, van der Maarel MJEC, Meulenbergh R, Menke H, Mortimer AM, Nielsen J, Oliver SG, Olsthoorn M, Pal K, van Peij NNME, Ram AFJ, Rinas U, Roubos JA, Sart CMJ, Schinnol M, Sun J, Ussery D, Varga J, Vervecken W, van der Vondervoort PJ2, Wedler H, Wosten HAB, Zeng A-P, van Ooyen AJJ, Visser J and Stam H, 2007. Genome sequencing and analysis of the versatile cell factory Aspergillus niger strain CBS 513.88. Nature Biotechnology, 25, 221-231. https://doi.org/10.1038/nbt1282

Selten GCM, Swinkels BW and Bovenberg RAL, 1998. Gene conversion as a tool for the construction of recombinant filamentous fungi. International Patent Application WO 98/46772

Snoek IS, van der Krogt ZA, Touw H, Kerkman R, Pronk JT, Bovenberg RAL, van den Berg MA and Daran JM, 2009. Construction of an hdfla Penicillium chrysogenum strain impaired in non-homologous end-joining and its application for functional analysis studies. Fungal Genetics and Biology., 46, 418-426. https://doi.org/10.1016/j.fgb.2009.02.008

Takasaki S, Kato Y, Murata M, Homma S and Kawakishi S, 2005. Effects of peroxidase and hydrogen peroxide on the dityrosine formation and the mixing characteristics of wheat-flour dough. Bioscience, Biotechnology, and Biochemistry, 69, 1686–1692. https://doi.org/10.1271/bbb.69.1686

Tilley KA, Benjamin RE, Bagorogoza KE, Okot-Kotber BM, Prakash O and Kwen H, 2001. Tyrosine cross-links: molecular basis of gluten structure and function. Journal of Agriculture and Food Chemistry, 49, 2627–2632. https://doi.org/10.1021/jf010113h
Wirsel S, Lachmund A, Wildhardt G and Ruttkowski E, 1989. Three alpha-amylase genes of Aspergillus oryzae exhibit identical intron-exon organization. Molecular Microbiology, 3, 3–14. https://doi.org/10.1111/j.1365-2958.1989.tb00097.x

Zargari A, Selander C, Rasool O, Ghanem M, Gadda G, Crameri R and Scheynius A, 2007. Mala s 12 is a major allergen in patients with atopic eczema and has sequence similarities to the GMC oxidoreductase family. Allergy, 62, 695–703. https://doi.org/10.1111/j.1398-9995.2006.01291.x

Abbreviations

ASPU Asparaginase Unit
ABTS 2,2'-azino-bis-3-ethylbenzthiazoline-6-sulphonic acid
bp base pair
bw body weight
CAS Chemical Abstracts Service
CBS Centraalbureau voor Schimmelcultures
CEF EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CEP EFSA Panel on Food Contact Materials, Enzymes and Processing Aids
CFU colony forming units
EC European Commission and Enzyme Commission
EINECS European Inventory of Existing Commercial Chemical Substances
FAO Food and Agricultural Organization of the United Nations
GLP Good Laboratory Practice
GMC glucose-methanolcholine
GMO Genetically Modified Organisms
GMP Good Manufacturing Practice
GOPU Glucose Oxidase from Penicillium Unit
HACCP Hazard Analysis and Critical Control Points
IgE immunoglobulin E
IUBMB International Union of Biochemistry and Molecular Biology
JECA Joint FAO/WHO Expert Committee on Food Additives
LOD limit of detection
LOQ limit of quantification
MoE margin of exposure
NOAEL no observed adverse effect level
OECD Organisation for Economic Cooperation and Development
PCR polymerase chain reaction
SDS-PAGE sodium dodecyl sulfate–poly acrylamide gel electrophoresis
TOS total organic solids
WHO World Health Organization
Appendix A – Dietary exposure estimates to the food enzyme–TOS in details

Information provided in this appendix is shown in an excel file (downloadable https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.5629).

The file contains two sheets, corresponding to two tables.

Table 1: Average and 95th percentile exposure to the food enzyme–TOS per age class, country and survey.

Table 2: Contribution of food categories to the dietary exposure to the food enzyme–TOS per age class, country and survey.
## Appendix B – Population groups considered for the exposure assessment

| Population   | Age range                                      | Countries with food consumption surveys covering more than one day |
|--------------|------------------------------------------------|-------------------------------------------------------------------|
| Infants      | From 12 weeks on up to and including 11 months of age | Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Portugal, United Kingdom |
| Toddlers     | From 12 months up to and including 35 months of age | Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Netherlands, Portugal, Spain, United Kingdom |
| Children(a)  | From 36 months up to and including 9 years of age | Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Italy, Latvia, Netherlands, Portugal, Spain, Sweden, United Kingdom |
| Adolescents  | From 10 years up to and including 17 years of age | Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Netherlands, Portugal, Spain, Sweden, United Kingdom |
| Adults       | From 18 years up to and including 64 years of age | Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Portugal, Romania, Spain, Sweden, United Kingdom |
| The elderly(a) | From 65 years of age and older | Austria, Belgium, Denmark, Estonia, Finland, France, Germany, Hungary, Ireland, Italy, Latvia, Netherlands, Portugal, Romania, Spain, Sweden, United Kingdom |

(a): The terms ‘children’ and ‘the elderly’ correspond, respectively, to ‘other children’ and the merge of ‘elderly’ and ‘very elderly’ in the Guidance of EFSA on the ‘Use of the EFSA Comprehensive European Food Consumption Database in Exposure Assessment’ (EFSA, 2011).